STOCK TITAN

Citius Oncology grants CFO 400,000 stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Citius Oncology, Inc. (CTOR) granted Chief Financial Officer Jaime Bartushak 400,000 stock options on November 9, 2026, with an exercise price of $0.5495 per share and an expiration date of November 9, 2036. The award is subject to continuous service on applicable vesting dates. Bartushak also reported direct ownership of 825,000 common shares and direct option positions covering 400,000 shares at a $1.07 exercise price, expiring December 12, 2034, and 1,400,000 shares at $2.15, expiring July 5, 2033.

Insider Bartushak Jaime
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 400,000 $0.00 $0.00
Holding Stock Option (Right to Buy) F2 -- -- --
Holding Stock Option (Right to Buy) F3 -- -- --
Holding Common Stock -- -- --
Holdings After Transaction: Stock Option (Right to Buy) — 2,200,000 options, with 1,800,000 underlying shares of Common Stock (Direct); Common Stock — 825,000 shares (Direct)
Footnotes (3)
  1. F1. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
  2. F2. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
  3. F3. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
Options granted 400,000 options covering 400,000 common shares Granted to CFO Jaime Bartushak on November 9, 2026
Exercise price $0.5495 per share Options granted November 9, 2026; expiration date November 9, 2036
Direct common shares held 825,000 shares Reported by Jaime Bartushak on November 9, 2026
Existing options at $1.07 400,000 underlying common shares Direct option position; expiration date December 12, 2034
Existing options at $2.15 1,400,000 underlying common shares Direct option position; expiration date July 5, 2033
Continuous Service technical
"subject to the Reporting Person's Continuous Service"
exercise price financial
"conversion_or_exercise_price of $0.5495"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did CTOR CFO Jaime Bartushak receive?

Jaime Bartushak, Citius Oncology's chief financial officer, received 400,000 stock options on November 9, 2026. They have a $0.5495-per-share exercise price and expire November 9, 2036.

What is the vesting schedule for CTOR CFO Jaime Bartushak's options?

One-third vests on each of the one-year, two-year and three-year anniversaries of the November 9, 2026 grant date, provided Bartushak remains in Continuous Service to Citius Oncology or a Related Entity on each applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bartushak Jaime

(Last)(First)(Middle)
C/O CITIUS ONCOLOGY, INC.
11 COMMERCE DRIVE, 1ST FLOOR

(Street)
CRANFORD NEW JERSEY 07016

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CITIUS ONCOLOGY, INC. [ CTOR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock825,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.549511/09/2026A400,000 (1)11/09/2036Common Stock400,000$0400,000D
Stock Option (Right to Buy)$1.07 (2)12/12/2034Common Stock400,000400,000D
Stock Option (Right to Buy)$2.15 (3)07/05/2033Common Stock1,400,0001,400,000D
Explanation of Responses:
1. These options were granted on November 9, 2026. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to Citius Oncology, Inc. (the "Company") or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
2. These options were granted on December 12, 2024. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the grant date, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
3. These options vest over three years, beginning July 5, 2023, with 1/36th every month for the first year, and the 1/3 each on the second and third anniversary of the July 5, 2023, subject to the Reporting Person's Continuous Service to the Company or a Related Entity (as defined in the award agreement) as of the applicable vesting date.
/s/ Alexander M. Donaldson, by Power of Attorney11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading